The use of nicotine gum as a therapeutic agent is based on the assumption that smokers smoke for nicotine.
The evidence supporting nicotine as the dependency-producing agent is suggestive but inconclusive. The dependency premise has led to proposals of nicotine regulation or "titration." That is. it has been assumed that smokers. once dependent, regulate nicotine through relatively stable patterns of self-administration. Data supporting the nicotine regulation model come mostly from experiments showing variation in smoking rates accompanying experimental manipulation of nicotine levels (for example, e.g., Mangan and Golding, 1978; Herning et al. 1981) .
However, the regulation in most studies is imprecise. Some investigations. especially those correlating nicotine yield and nicotine blood levels, have failed to demonstrate a regulation effect (Kumar et al. 1977) .
Initial trials with nicotine gum conducted in Great Britain and other European countries produced mixed results. Russell et al. (1976) compared 2 mg nicotine chewing gum with placebo in a double-blind cross-over trial during which 43 smokers were either smoking "as inclined" or were attempting cessation. Use of the gum signficantly reduced smoking during the ad lib period, but differences between the two conditions disappeared when subjects attempted to quit smoking. At 6-month followup, Puska et al. (1979) found 35% abstinence for nicotine gum treatment subjects and 25% for placebo. Malcolm et al. (1980) found 23% abstinence for gum treated subjects, 5% for placebo, and 14% for a no-drug control. Recent studies reported by Russell have produced higher abstinence rates, probably due to improvements in the formulation of the gum and to better instructions in its use. One year COH b validated abstinence rates of 38% have been reported (Russell et al. 1980) . These may be increased to 67-68% for subsample which continue to use the gum for at least four months (Russell et al. 1980; Wilhelmson and Hjalmarsson 1980) . However, at least one recent placebo-controlled trial has failed to demonstrate an effect for the active gum (British Thoracic Society 1983) . and two others reported failures to maintain initial significant differences at 1-year assessments (Fagerstrom 1982; Fee and Stewart 1982) . a negative result replicated in a sample from the United States (Schneider et al. 1983 ).
ADVANCED PSYCHOLOGICAL TREATMENTS
Multicomponent psychological interventions represent "state-of-theart" efforts in psychosocial approaches to smoking cessation the relapse prevention (e.g.. Hall 1984) . Treatments typically combine aversive smoking strategies to produce quitting with behavioral skill training.
The skill training gives clients skills to successfully overcome high risk situations.
Results from controlled investigations of multicomponent programs have been mixed. Although some have reported 12-month abstinence rates above 50% (Delahunt and Curran 1976; Lando 1977) , the data from most of these studies are less than persuasive. Rates are either lower (e.g., Danaher 1977) . or they are based on selfreported abstinence without biochemical verification.
COMBINING PSYCHOLOGICAL AND PHARMACOLOGICAL APPROACHES
Most investigators agree that both psychological and pharmacologic factors maintain smoking (Jaffe and Kanzler 1979). Therefore, procedures enabling quitters to cope with the psychological factors precipitating relapse combined with pharmacological management of withdrawal symptoms may enhance long-term treatment outcomes. In one such trial. Fagerstrom (1982) reported a 12-month abstinence rate of 49%.
The two trials reported in this paper combined nicotine gum with similar multicomponent psychological interventions.
The studies were designed and executed independently. One was Implemented at Stanford University (Killen) , the other at the University of California, San Francisco (Hall) .
THE STANFORD TRIAL
Sixty-four subjects were assigned to one of three maintenance treatment conditions:
(1) nicotine gum (n=22); (2) skills training (n=20); (3) combined.
The latter included gum plus skills training (n=22). Abstinence was assessed at 6 and 15 weeks and 10.5 months following cessation.
Expired air carbon monoxide levels were measured at all three points. Serum thiocyanate levels were collected at 6 weeks.
Subjects
Subjects met the following criteria: (1) did not present cardiovascular cr pulmonary disease symptoms; (2) were not pregnant; (3) paid a 50 dollar deposit; and (4) obtained physician's consent to participate.
Subject characteristics are presented in table 1. All subjects participated in the cessation phase, designed to produce rapid quitting.
Therapists met with participants in groups of 10-12 in four consecutive 1.5-hour sessions.
All smoking was expected to cease after the third session so that subjects would have achieved abstinence for 24 hours at session four.
During the first hour of each session, a four-step skills training procedure was used to help participants develop strategies for coping with the multiple determinants of smoking.
In Step 1. self-efficacy scales developed by Condiotte and Lichtenstein (1981) were used to target high-risk situations.
In
Step 2, therapists led group members in a discussion of potentially effective coping strategies. In Step 3, therapists demonstrated how strategies for selected target situations might be implemented.
Step 4. participants rehearsed responses specific to personal high-risk situations in front of the group.
Therapists and group members provided feedback following each rehearsal.
During the final 30 minutes of each session participants engaged in an aversive smoke holding procedure.
Imagery training with home practice was used with smoke holding to promote more potent, self-regulated use of aversion effects.
Maintenance Phase Condition 1: nicotine gum. Subjects in this condition used nicotine gum (2 mg) for 7 weeks.
Nicotine gum was begun on day 1 of the cessation phase. Participants were informed that-a variety of psychophysiological withdrawal symptoms accompany cessation and may increase the chance of relapse.
They were instructed to chew nicotine gum at each occurrence of an urge, craving, or other symptom; they were told that symptoms would diminish within 10 to 15 minutes of onset.
Participants were also told that the gum was only viewed as an adjunct to cessation, and that skill development and practice were essential to continued abstinence.
They were instructed to reduce gum usage beginning in week 3 in order to terminate gum use completely at the end of treatment. Gum was not available beyond week 7.
During the maintenance phase, participants in Condition 1 attended a drop-in clinic for 20 minutes once a week beginning in week 2. At each session participants received new gum supplies if desired and returned unused portions of gum allotments distributed at the previous session. Carbon monoxide levels were measured and selfregulatory efficacy scales were completed.
Portions of the $50 deposit were returned for attending weekly sessions.
Condition 2: skills training. Participants in Condition 2 met in small, therapist-led groups during weeks 2 and 3 for additional skills training designed to strengthen nonsmoking skills. Nicotine gum was not administered.
In weeks 4-7 they directed their own maintenance program and received performance feedback during weekly drop-in clinic sessions.
Participants used efficacy scales to target high-risk situations and wrote treatment plans detailing the (a) problem situation; (b) appropriate coping strategies; (c) change plan implementation procedures; and (d) outcomes. Portions of the deposit were returned for completion of weekly homework assignments.
Condition 3: combined. During the maintenance phase, participants in Condition 3 received the skills training program developed for those in Condition 2 (ST).
They also began; nicotine gum on day 1 and discontinued use at the end of treatment (week 7). (ST) (X 2 =3.63, p<.05, one-tailed), but not different from the gum only format (NG). At 10.5 months, differences between the gum formats were not significant at (p<.O5) but were in the predicted direction (X 2 =2.46, p<.10, one-tailed). Carbon monoxide values were used to verify self-report: at each assessment.
Thiocyanate was used to verify reports at 6 weeks.
Ninety percent agreement was obtained between biochemical measures.
Withdrawal Symptoms
A Tobacco Withdrawal Scale, developed by Bachman (unpublished) was used to assess the frequency and severity of withdrawal symptoms associated with cessation.
Subjects rated the severity of each of 24 symptoms on a scale ranging from 0 (no symptom) to 4 (extremely severe). Withdrawal symptoms were collected daily during weeks 2-4. At week 3. gum users reported significantly less severe symptoms t(48)=2.39, (p<.O5).
Differences at weeks 2 and 4 were not significant but in the predicted direction.
Physical Dependence Predictors
A stepwise logistic regression analysis was conducted to examine the utility of seven factors (Fagerstrom Tolerance Questionnaire, reported cigarette consumption, withdrawal symptom severity, urge severity, cotinine, expired-air carbon monoxide and serum thiocyanate) in predicting resumption of smoking. Urge severity accounted for about 14% of the relapse variance (X 2 =10.93,p<.009) at the 15-week followup.
Symptom severity accounted for about 3% of the variance (X 2 =3.95,p<.05). Suprisingly. cotinine failed to predict relapse at any assessment.
Side Effects of Gum Use
Most users reported some side effects, but only three discontinued use due to personal discomfort. Table 3 presents the most frequently reported side effects. Subjects were assigned by order of entrance into treatment to one of three treatment conditions. These were nicotine gum in a low contact group, entensive behavioral, or combined.
All subjects were told to stop smoking on the first day of treatment and were precautioned against smoking outside the sessions thereafter. All meetings lasted 75 minutes. This treatment was modeled on that studied earlier in the senior author's laboratory. In that trial, it produced 50% abstinence rate at 6 months. and 39% at 1 year (Hall et al. 1982) . The treatment had two phases, a quitting phase and a relapse prevention phase. The quitting phase consists of eight aversive smoking sessions held during the first 3 weeks.
Subjects puffed and inhaled every 30 seconds. Videotape feedback of the smoking sessions was used to provide negative images for the smoker to use when tempted to smoke outside the session. Carbon monoxide feedback was given before and after each treatment session, to emphasize the physical effects of smoking.
The relapse prevention phase had three components. These were relaxation training, smoking situation training, and structured feedback. Subjects were taught a modification of Benson's (1974) relaxation method.
They made a commitment to use this technique or another of their choosing to combat feelings of tension and irritability. Subjects role-played typical relapse situations and learned ways of rethinking responses to urges. Structured feedback consisted of paper and pencil exercises with group discussion on the costs of smoking and the benefits of quitting. CO levels were also used as feedback during this phase of treatment.
Nicotine Gum plus Low Contact Group
Four treatment sessions were held over a 3-week period. Subjects were given detailed instructions in use of nicotine gum, including when and how to taper off the gum.
During treatment sessions, use of the gum was monitored, reading materials were discussed, and individual plans to quit smoking were formulated. As part of that plan, subjects made a commitment to the group to use specific strategies.
Materials presented included three booklets: a tip sheet taken from the American Cancer Society, information on the American Lung Association Tel-Med Phone line, and a magazine article on nicotine gum. Gum was available for 6 months from study start.
Combined Treatment
The combined treatment was identical to the behavioral treatment except that nicotine gum and instructions in its use were provided and gum was available for 6 months from study start.
Assessments were held at weeks 0 (pretreatment), 3 (posttreatment). 12, 26. and 52. Abstinence was verified by CO. Plasma thiocyanate analyses were used to verify abstinence at 26 and 52 weeks. Blood cotinine and Tolerance Scores were collected at pretreatment.
RESULTS
Abstinence rates are shown In table 5. Differences between the Combined condition and the two single modality treatment conditions considered together were significant at weeks 3 (X 2 (1)=5.00, p<.O2), 12 (X 2 (1)=4.50, p<.O3), and 26 (X 2 (1)=4.05, p<.04), but not at week 52 (X 2 (1)=1.40, p<0.24).
Hierarchial logistic regression indicated significant treatment condition by cotinine level interventions.
For subjects above the median, differences in abstinence rates between gum and no gum conditions were significant at all assessments at week 3 (X 2 (1)= 3.89, p<.05, 26 (X 2 (1)-4.71, p<.O3), and 52 (X 2 (l)= 5.31, p<.05). A nonsignificant trend in the same direction was noted at week 12 (X 2 =2.97, p<.08).
There were no significant differences between gum and no gum conditions for subjects below the cotinine median.
Results for the Tolerance Scale followed a similar pattern, but differences between gum and no gum for subjects above the median were significant only at weeks 12 (p<.026) and 26 (p<.O27). Cigarettes per day showed a similar pattern, but differences were significant only at week 26 (p<.O34).
Abstinence rates at each assessment for both gum and no gum conditions for subjects above and below the median on cotinine are shown in table 6. 13 (68) 7 (37) 3 (16) 2 (11)
30 (al) 15 (88) 23 (62) 10 (58) 18 (49) 8 (47) 15 (41) 8 (47) The two studies produced similar outcomes. In both, the intensive behavioral treatment combined with nicotine chewing gum produced some of the highest longer term abstinence rates ever reported, especially in relatively early assessments. Biochemical verification of self-reported abstinence strengthens the persuasiveness of the findings.
The results suggest that nicotine gum should be combined with considerable psychological support.
While the short-term performance of subjects in Killen's gum-only format was encouraging, only 23% remained abstinent at 45 weeks.
Relapse rates for the other conditions were not nearly so marked.
Subjects in the gum-only format may have been less prepared to cope with psychological factors, since their exposure to the behavioral intervention was brief.
Hall's low contact condition did not produce nearly so sharp a relapse rate. Of these subjects, 37% were abstinent at 1 year. Several factors may have contributed to differences between the two studies, including the long period of gum availability for Hall's subjects, or the emphasis on self-reliance in the low contact groups, or the formulation of a plan and commitment to use it. It should be noted, however, that in both studies even the low contact conditions provided more support than patients will probably receive when the gum is administered as a prescription drug.
Physicians should be cautioned that mere prescription of the gum cannot be expected to produce optimal performance. Psychological and behavioral factors clearly influence outcomes and must be addressed if treatments are to produce durable results.
How the gum will be combined with behavioral treatments in clinical practice is unclear, and is likely to be neglected unless considerable effort is directed to physician education.
Research designed to develop and evaluate physician-administered treatments combining both nicotine and psychological interventions is clearly needed.
Controlled placebo comparison trials testing the effects of the gum and standardized psychological treatments are essential to clarify the importance of different mechanisms in the change process. Fagerstrom (1982) has reported 6-month abstinence rates of 63% and 45% for active and placebo gum combined with psychological therapy. Fee and Stewart (1982) reported posttreatment rates of 46% and 33% for active and placebo gum respectively. Given their sample sizes, the 18% difference reported by Fagerstrom and the 13% difference reported by Fee and Stewart were statistically significant. However, the so-called placebo effect of the gum would appear to be important, since abstinence rates in both placebo conditions were respectable.
Thus, as Russell notes (this volume), the placebo effect can be used to advantage.
It should also be noted that significant differences between the active and placebo gums vanished at 12-month followups in both reports.
Periods of gum availability have ranged from 5 weeks (Fee and Stewart, 1982 ) to 1 year (Schneider et al. 1984) . Research on different gum administration schedules is also needed. Russell (1980) suggested that nicotine gum be available for at least 4 months.
The data are mixed, but relapse may be, in part, a function of the effects of tobacco dependence.
However, we know very little of the process by which presumed psychological and pharmacological manifestations of dependence promoted relapse (Jarvik 1979).
The Stanford and UCSF trials examined several biochemical and self-report measures of physical dependence.
Previous work suggests that cotinine may be a useful measure of chronic tobacco dependence and might serve to identify those smokers most likely to relapse following smoking cessation (Hall et al. 1984b; Zeidenberg et al. 1977) .
Findings from Hall's study support the earlier work. Subjects above the median cotinine level did poorly without nicotine gum. Availability of the gum had little effect for subjects below the median.
Killen's data showed no correlation between cotinine levels and abstinence.
Reasons for differences in outcome are unclear.
Blood samples were drawn in Hall's study after an 8-to 12-hour cigarette fast.
Thus, the levels reported represent constant levels, unconfounded by length of time since last cigarette. This was not the case in Killen's sample, where time since last cigarette was not controlled.
However, this procedural difference cannot entirely account for the differences between the two studies, since Hall et al. (1984b) used procedures similar to those of Killen in earlier work, and were able to predict outcome. In Hall's sample, cotinine was an especially good predictor when a median split was used, suggesting measurement at some points of the distribution may be more reliable than at others.
The Fagerstrom Tolerance Questionnaire was also examined in both trials.
Prediction of relapse was reasonably good only in the UCSF study.
Killen also examined measures of withdrawal symptoms severity and urge severity.
Reported urge severity accounted for about 14% of the relapse variance at the 15-week followup. This is one of the first studies to demonstrate a relationship between urge, strength and relapse. Although modest, the level of prediction achieved with this measure compares well with the predictive power of measures such as self-efficacy or cotinine which typically account for between 10% and 15% of the variance in treatment outcome. The results suggest that further efforts to develop measures of smoking urge may be warranted.
